Antiviral Therapies Market , By Drug Type (Herpes Antiviral Drugs, Hepatitis Antiviral Drugs, HIV Antiviral Drugs, Influenza Antiviral Drugs, Others), By Distribution Channel (Hospital Pharmacy, Independent Pharmacy & Drug Store, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2019–2026
- RES4072070
- 270 Pages
- February 2020
- Healthcare
The global Antiviral Therapies market is categorized by drug type into herpes antiviral drugs, hepatitis antiviral drugs, HIV antiviral drugs, influenza antiviral drugs and others. The HIV antiviral drugs accounted for the highest market share of 34.0% in the year 2018, and is anticipated to continue its dominance over the forecast period. According to report published by UNAIDS, in the year 2018 around 37.9 million of the global population were tested HIV positive.
The cost associated with the antiviral therapies is the key factor hindering the market growth. Additionally, the rapid growth in the usage of natural products coupled with the high development cost required to develop antiviral drugs are acting as the key market hindering factors.
On the basis of drug type, the market is divided into herpes antiviral drugs, hepatitis antiviral drugs, HIV antiviral drugs, and influenza antiviral drugs among others. HIV antiviral drugs held the largest market share in the year 2018 accounting for 34%. Herpes antiviral drugs segment in antiviral therapies market is anticipated to experience a swift growth over the forecast period growing at a CAGR of 6.1% by 2026.
By end-use, the global antiviral therapies market has been segmented into hospital pharmacies, independent pharmacy & drug store, online pharmacy and others. Online pharmacies segment is expected to experience the lucrative growth over the forecast period due rising adoption of online shopping trend in the developed as well as developing nations such as U.S., Canada, India and China.
Based on the region, the global antiviral therapies market has been studied across North America, Europe, Asia-Pacific, and LAMEA. In the year 2018, North America region accounted 32% of the global market share. This is majorly due to the presence of number of key players in this region and rapid growth in the adoption of new technologies by the people. Additionally, lack of knowledge and unavailability of antiviral drugs in Asia-pacific region is expected to create new growth opportunities over the forecast period.
Top players in the Antiviral Therapies market are Gilead Sciences, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., AbbVie, AbbVie Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma and Dr. Reddy’s Laboratories Ltd. These key players in Antiviral Therapies markets are concentrating on developments in the present technology, new product launches, geographical expansions, and mergers & acquisitions, and are the key strategies focused by these companies.
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.4.1. Assumptions
1.4.2. Forecast parameters
1.5. Data sources
1.5.1. Primary
1.5.2. Secondary
2. Executive Summary
2.1. 360° summary
2.2. Drug Type trends
2.3. Distribution Channel trends
3. Market Overview
3.1. Market segmentation & definitions
3.2. key takeaways
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of consumers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of new entrants
3.3.4. Threat of substitutes
3.3.5. Competitive rivalry in the market
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Distribution Channel landscape
3.6. Regulatory landscape
3.7. Patent landscape
3.8. Market value chain analysis
3.9. Strategic overview
4. Anti-Viral Therapies Market, by Drug Type
4.1. Herpes Antiviral Drugs
4.1.1. Market size and forecast, by region, 2016-2026
4.1.2. Comparative market share analysis, 2018 & 2026
4.2. Hepatitis Antiviral Drugs
4.2.1. Market size and forecast, by region, 2016-2026
4.2.2. Comparative market share analysis, 2018 & 2026
4.3. HIV Antiviral Drugs
4.3.1. Market size and forecast, by region, 2016-2026
4.3.2. Comparative market share analysis, 2018 & 2026
4.4. Influenza Antiviral Drugs
4.4.1. Market size and forecast, by region, 2016-2026
4.4.2. Comparative market share analysis, 2018 & 2026
4.5. Others
4.5.1. Market size and forecast, by region, 2016-2026
4.5.2. Comparative market share analysis, 2018 & 2026
5. Anti-Viral Therapies Market, by Distribution Channel
5.1. Hospitality Pharmacy
5.1.1. Market size and forecast, by region, 2016-2026
5.1.2. Comparative market share analysis, 2018 & 2026
5.2. Independent Pharmacy and Drug Store
5.2.1. Market size and forecast, by region, 2016-2026
5.2.2. Comparative market share analysis, 2018 & 2026
5.3. Online Pharmacy
5.3.1. Market size and forecast, by region, 2016-2026
5.3.2. Comparative market share analysis, 2018 & 2026
6. Anti-Viral Therapies Market, by Region
6.1. North America
6.1.1. Market size and forecast, by Drug, 2016-2026
6.1.2. Market size and forecast, by Distribution Channel, 2016-2026
6.1.3. Market size and forecast, by country, 2016-2026
6.1.4. Comparative market share analysis, 2018 & 2026
6.1.5. U.S.
6.1.5.1. Market size and forecast, by Drug, 2016-2026
6.1.5.2. Market size and forecast, by Distribution Channel, 2016-2026
6.1.5.3. Comparative market share analysis, 2018 & 2026
6.1.6. Canada
6.1.6.1. Market size and forecast, by Drug, 2016-2026
6.1.6.2. Market size and forecast, by Distribution Channel, 2016-2026
6.1.6.3. Comparative market share analysis, 2018 & 2026
6.1.7. Mexico
6.1.7.1. Market size and forecast, by Drug, 2016-2026
6.1.7.2. Market size and forecast, by Distribution Channel, 2016-2026
6.1.7.3. Comparative market share analysis, 2018 & 2026
6.2. Europe
6.2.1. Market size and forecast, by Drug, 2016-2026
6.2.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.3. Market size and forecast, by country, 2016-2026
6.2.4. Comparative market share analysis, 2018 & 2026
6.2.5. UK
6.2.5.1. Market size and forecast, by Drug, 2016-2026
6.2.5.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.5.3. Comparative market share analysis, 2018 & 2026
6.2.6. Germany
6.2.6.1. Market size and forecast, by Drug, 2016-2026
6.2.6.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.6.3. Comparative market share analysis, 2018 & 2026
6.2.7. France
6.2.7.1. Market size and forecast, by Drug, 2016-2026
6.2.7.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.7.3. Comparative market share analysis, 2018 & 2026
6.2.8. Spain
6.2.8.1. Market size and forecast, by Drug, 2016-2026
6.2.8.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.8.3. Comparative market share analysis, 2018 & 2026
6.2.9. Italy
6.2.9.1. Market size and forecast, by Drug, 2016-2026
6.2.9.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.9.3. Comparative market share analysis, 2018 & 2026
6.2.10. Rest of Europe
6.2.10.1. Market size and forecast, by Drug, 2016-2026
6.2.10.2. Market size and forecast, by Distribution Channel, 2016-2026
6.2.10.3. Comparative market share analysis, 2018 & 2026
6.3. Asia-Pacific
6.3.1. Market size and forecast, by Drug, 2016-2026
6.3.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.3. Market size and forecast, by country, 2016-2026
6.3.4. Comparative market share analysis, 2018 & 2026
6.3.5. China
6.3.5.1. Market size and forecast, by Drug, 2016-2026
6.3.5.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.5.3. Comparative market share analysis, 2018 & 2026
6.3.6. Japan
6.3.6.1. Market size and forecast, by Drug, 2016-2026
6.3.6.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.6.3. Comparative market share analysis, 2018 & 2026
6.3.7. India
6.3.7.1. Market size and forecast, by Drug, 2016-2026
6.3.7.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.7.3. Comparative market share analysis, 2018 & 2026
6.3.8. Australia
6.3.8.1. Market size and forecast, by Drug, 2016-2026
6.3.8.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.8.3. Comparative market share analysis, 2018 & 2026
6.3.9. South Korea
6.3.9.1. Market size and forecast, by Drug, 2016-2026
6.3.9.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.9.3. Comparative market share analysis, 2018 & 2026
6.3.10. Rest of Asia-Pacific
6.3.10.1. Market size and forecast, by Drug, 2016-2026
6.3.10.2. Market size and forecast, by Distribution Channel, 2016-2026
6.3.10.3. Comparative market share analysis, 2018 & 2026
6.4. LAMEA
6.4.1. Market size and forecast, by Drug, 2016-2026
6.4.2. Market size and forecast, by Distribution Channel, 2016-2026
6.4.3. Market size and forecast, by country, 2016-2026
6.4.4. Comparative market share analysis, 2018 & 2026
6.4.5. Brazil
6.4.6. Market size and forecast, by Drug, 2016-2026
6.4.7. Market size and forecast, by Distribution Channel, 2016-2026
6.4.8. Comparative market share analysis, 2018 & 2026
6.4.9. Saudi Arabia
6.4.9.1. Market size and forecast, by Drug, 2016-2026
6.4.9.2. Market size and forecast, by Distribution Channel, 2016-2026
6.4.9.3. Comparative market share analysis, 2018 & 2026
6.4.10. South Africa
6.4.10.1. Market size and forecast, by Drug, 2016-2026
6.4.10.2. Market size and forecast, by Distribution Channel, 2016-2026
6.4.10.3. Comparative market share analysis, 2018 & 2026
6.4.11. Rest of LAMEA
6.4.11.1. Market size and forecast, by Drug, 2016-2026
6.4.11.2. Market size and forecast, by Distribution Channel, 2016-2026
6.4.11.3. Comparative market share analysis, 2018 & 2026
7. Company Profiles
7.1. AbbVie, Inc.
7.1.1. Business overview
7.1.2. Financial performance
7.1.3. Drug portfolio
7.1.4. Recent strategic moves & developments
7.1.5. SWOT analysis
7.2. Bristol-Myers Squibb Company
7.2.1. Business overview
7.2.2. Financial performance
7.2.3. Drug portfolio
7.2.4. Recent strategic moves & developments
7.2.5. SWOT analysis
7.3. Cipla, Inc.
7.3.1. Business overview
7.3.2. Financial performance
7.3.3. Drug portfolio
7.3.4. Recent strategic moves & developments
7.3.5. SWOT analysis
7.4. F. Hoffman-La Roche Ltd.
7.4.1. Business overview
7.4.2. Financial performance
7.4.3. Drug portfolio
7.4.4. Recent strategic moves & developments
7.4.5. SWOT analysis
7.5. Gilead Sciences Inc.
7.5.1. Business overview
7.5.2. Financial performance
7.5.3. Drug portfolio
7.5.4. Recent strategic moves & developments
7.5.5. SWOT analysis
7.6. GlaxoSmithKline plc.
7.6.1. Business overview
7.6.2. Financial performance
7.6.3. Drug portfolio
7.6.4. Recent strategic moves & developments
7.6.5. SWOT analysis
7.7. Merck & Co.
7.7.1. Business overview
7.7.2. Financial performance
7.7.3. Drug portfolio
7.7.4. Recent strategic moves & developments
7.7.5. SWOT analysis
7.8. Johnson & Johnson Services, Inc.
7.8.1. Business overview
7.8.2. Financial performance
7.8.3. Drug portfolio
7.8.4. Recent strategic moves & developments
7.8.5. SWOT analysis
7.9. Aurobindo Pharma
7.9.1. Business overview
7.9.2. Financial performance
7.9.3. Drug portfolio
7.9.4. Recent strategic moves & developments
7.9.5. SWOT analysis
7.10. Dr. Reddy’s Laboratories Ltd.
7.10.1. Business overview
7.10.2. Financial performance
7.10.3. Drug portfolio
7.10.4. Recent strategic moves & developments
7.10.5. SWOT analysis
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
